In times past, biotechnology companies were relatively naïve on the terms of a deal to license their product to pharmaceutical companies. A good pharma trick used to be to allow the biotech partner to opt-in on the joint development of the licensed product so that lower upfront milestone payments could be traded for a bigger slice of the downstream commercialization pie. Unfortunately as companies like GenMab and Celltech later found (scripintelligence.com, 2 July 2010 and 19 November 2003), this development commitment rapidly became a millstone around their necks and led to renegotiated terms which favored the pharmaceutical company.
STOCKWATCH: European approval - milestone or millstone?
In times past, biotechnology companies were relatively naïve on the terms of a deal to license their product to pharmaceutical companies. A good pharma trick used to be to allow the biotech partner to opt-in on the joint development of the licensed product so that lower upfront milestone payments could be traded for a bigger slice of the downstream commercialization pie. Unfortunately as companies like GenMab and Celltech later found (scripintelligence.com, 2 July 2010 and 19 November 2003), this development commitment rapidly became a millstone around their necks and led to renegotiated terms which favored the pharmaceutical company.
More from Musculoskeletal
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
• By
The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
More from Therapeutic Category
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.